627-75-8

应用筛选条件

关键词:'627-75-8'

显示 1-1 共 1 条结果关于 "627-75-8" 范围论文

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Edward B Garon et al.

Lancet (London, England), 384(9944), 665-673 (2014-06-17)

Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC)

1/1